Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Comment by forhandlarenon Apr 11, 2024 12:34pm
86 Views
Post# 35983581

RE:RE:RE:Update

RE:RE:RE:UpdateSounds like you're just blind by bitterness. Basically it means that any positive message like a product launch would be considered useless to you just because the origin of the message is the mangement, kind of weird way to reason I guess.

I'm not happy at all with the current share price - and yes - that's mostly because of unexperienced management in the past, but my primary focus is on the new strategic direction that should have a very good chance to be successful and finally provide the ROI I've been looking for.

They are pretty transparent about the anti-aging progress which I think is well above average compared to other companies. The short term issue is obviously financing and they have shared the intended direction. That's good enough besides the depressing share price of course.
<< Previous
Bullboard Posts
Next >>